April Huseby Kelcher (April M Huseby Kelcher, April M H Kelcher)

Scopus Author ID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2021
Publications (10 Years): 4

Top Topics

Metabolic Syndrome

Electronic Health Record

Top Venues

Molecular pharmaceutics

Journal of immunology (Baltimore, Md. : 1950)

Science immunology

University of Minnesota

Mayo Graduate School (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Minnesota Dec 28 2018

United States

Postdoctoral Research Fellow :: Pharmacology/Psychiatry

Education History

Mayo Graduate School Jul 09 2012 - Sep 26 2017

United States

PHD :: Immunology

Publications

April Huseby Kelcher, Carly A Baehr, Fatima A Hamid, Geoffrey T Hart, Marco Pravetoni
Contribution of Antibody-Mediated Effector Functions to the Mechanism of Efficacy of Vaccines for Opioid Use Disorders. Journal of immunology (Baltimore, Md. : 1950) 207 (3) (2021)
Bethany Crouse, Christine Robinson, April Huseby Kelcher, Megan Laudenbach, Juan E Abrahante, Marco Pravetoni
Mechanisms of interleukin 4 mediated increase in efficacy of vaccines against opioid use disorders. NPJ vaccines 5 (2020)
Steven C Neier, Alejandro Ferrer, Katelynn M Wilton, Stephen E P Smith, April Huseby Kelcher, Kevin D Pavelko, Jenna M Canfield, Tessa R Davis, Robert J Stiles, Zhenjun Chen, James McCluskey, Scott R Burrows, Jamie Rossjohn, Deanne M Hebrink, Eva M Carmona, Andrew H Limper, Dietmar J Kappes, Peter J Wettstein, Aaron J Johnson, Larry R Pease, Mark A Daniels, Claudia Neuhauser, Diana Gil, Adam G Schrum
The early proximal αβ TCR signalosome specifies thymic selection outcome through a quantitative protein interaction network. Science immunology 4 (32) (2020)
Federico Baruffaldi, April Huseby Kelcher, Megan Laudenbach, Valeria Gradinati, Ajinkya Limkar, Michaela Roslawski, Angela Birnbaum, Andrew Lees, Carla Hassler, Scott Runyon, Marco Pravetoni
Preclinical Efficacy and Characterization of Candidate Vaccines for Treatment of Opioid Use Disorders Using Clinically Viable Carrier Proteins. Molecular pharmaceutics 15 (11) (2018)